to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)

NCT04301739 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

522

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple Negative Breast Cancer

Interventions

DRUG: HLX10
DRUG: nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide
DRUG: Placebo

Sponsor

Shanghai Henlius Biotech